Evaluation of the effectiveness of using prednisolone, tacrolimus, and intravenous immunoglobulin combination therapy on immune‐mediated necrotizing myopathy—A non‐randomized, observational research
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.15124 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Mengyang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Medical Center of Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Myositis, Autoimmune Diseases. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objective
To recruit immune‐mediated necrotizing myopathy (IMNM) patients with extramuscular manifestations who were refractory to initial therapy with either monotherapy with prednisolone or dual therapy with prednisolone and immunosuppressants. These patients subsequently received a combination of prednisolone, tacrolimus, and intravenous immunoglobulin (IVIG), and the efficacy of this treatment regimen was assessed in patients with IMNM. Method ①Clinical data and treatment measures are as follows: This study enrolled IMNM patients who were treated at the Neurology Department of the First Medical Center of PLA General Hospital from April 2020 to May 2023. These patients received a combination therapy of prednisolone, tacrolimus, and IVIG. ②Observational indicators included manual muscle test for 8 groups of muscles (MMT‐8), muscle enzyme levels (creatine kinase (CK), lactate dehydrogenase (LDH), alanine aminotransferase (ALT), aspartate aminotransferase (AST)), and myositis disease activity assessment tool (MDAAT).
Results
This study enrolled eight patients. All observational indicators declined after treatment compared to before treatment, and these changes were statistically significant. Moreover, extramuscular manifestations also ameliorated compared to before treatment.
Conclusion
The combination therapy of prednisolone, tacrolimus, and IVIG has demonstrated favorable efficacy in IMNM and broadened the treatment options for this disease. However, the results still require further validation by large‐scale and randomized controlled studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
- Medical School of Chinese PLA, Beijing, China.
- Department of Neurology, The Second Medical Center of Chinese PLA General Hospital, Beijing, China.
- Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China.
ORCID-Profile: Mengyang Liu, Qiang Shi
Zitieren
APA
Liu, M., Liu, J., Li, K., Qiao, L., Chen, J., Lin, Y., & Shi, Q. (2024). Evaluation of the effectiveness of using prednisolone, tacrolimus, and intravenous immunoglobulin combination therapy on immune‐mediated necrotizing myopathy—A non‐randomized, observational research. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15124
Vancouver
Liu M, Liu J, Li K, Qiao L, Chen J, Lin Y, et al. Evaluation of the effectiveness of using prednisolone, tacrolimus, and intravenous immunoglobulin combination therapy on immune‐mediated necrotizing myopathy—A non‐randomized, observational research. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15124
BibTeX
@article{Liu2024,
author = {Liu, Mengyang and Liu, Jiaqi and Li, Ke and Qiao, Lingya and Chen, Juan and Lin, Ying and Shi, Qiang},
title = {Evaluation of the effectiveness of using prednisolone, tacrolimus, and intravenous immunoglobulin combination therapy on immune‐mediated necrotizing myopathy—A non‐randomized, observational research},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.15124}
}
EUVIMED